持续抗凝患者接受180-W绿激光三硼酸锂激光前列腺选择性光汽化术的围手术期不良事件
回顾性分析2010至2016年373例接受180-W三硼酸锂激光前列腺选择性光汽化术的男性,其中59例持续抗凝。持续抗凝组与对照组围手术期不良事件总发生率无统计学显著差异(30.5% vs 19.9%,P=0.07),但持续抗凝组高级别Clavien-Dindo事件发生率有统计学显著差异(P=0.01)。作者认为持续抗凝与高级别Clavien-Dindo事件发生率升高相关,并建议谨慎将早期激光的安全性数据外推至当前180-W三硼酸锂激光。
要点
- 持续抗凝组与对照组围手术期不良事件总发生率无统计学显著差异(30.5% vs 19.9%,P=0.07)。
- 持续抗凝组高级别Clavien-Dindo事件发生率有统计学显著差异(P=0.01)。
- 持续抗凝组住院时间和导尿时间较对照组显著延长。
核心结论
- 持续抗凝治疗与围手术期不良事件总体增加无关,但与高级别Clavien-Dindo事件发生率升高相关。
- 作者认为,对于抗凝患者,将早期激光的安全性数据外推至当前180-W三硼酸锂激光时应谨慎。
研究设计与样本
- 回顾性分析2010至2016年接受180-W三硼酸锂激光前列腺选择性光汽化术的373例男性数据库。
- 373例中59例持续抗凝治疗,抗凝定义为使用肝素、华法林、氯吡格雷、双嘧达莫或新型口服抗凝药。
- 分析围手术期因素及术后90天内发生的不良事件。
主要发现
- 持续抗凝组与对照组围手术期不良事件总发生率分别为30.5% vs 19.9%,P=0.07,无统计学显著差异。
- 持续抗凝组高级别Clavien-Dindo事件发生率与对照组有统计学显著差异(P=0.01)。
- 无患者需要输血。
- 两组手术时间和能量使用无差异。
- 持续抗凝组59例中53例美国麻醉医师协会评分高,对照组272例中27例;持续抗凝组年龄也显著更大。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare perioperative factors and adverse events (AEs) in men undergoing photoselective vaporisation of the prostate (PVP) with or without continued anticoagulation therapy. PATIENTS AND METHODS: Retrospective review of a PVP database of men treated with the 180-W lithium triborate (LBO) laser from 2010 to 2016. Of 373 men, 59 underwent PVP with continued anticoagulant therapy, which was defined as treatment with heparin, warfarin, clopidogrel, dipyridamol or new oral anticoagulant drugs. Perioperative factors and AEs occurring within 90 days of surgery were analysed. RESULTS: There was no statistically significant difference in the overall incidence of perioperative AEs between those receiving and not receiving anticoagulation therapy (30.5% vs 19.9%, P = 0.07). However, there was a statistically significant difference in the incidence of high-grade Clavien-Dindo events in men who continued anticoagulation during PVP (P = 0.01). No men required blood transfusion. There was no difference in operative times and energy utilisation between the groups. In all, 53 of the 59 men in the anticoagulation group had a high-grade American Society of Anesthesiologists score, compared to 27 of the 272 men in the control group. The anticoagulation group were also significantly older. The anticoagulation group had a significantly longer length of hospital stay and duration of catheterisation compared to the controls. CONCLUSIONS: While continued anticoagulation therapy is not associated with an overall increase in perioperative AEs, it is associated with an increased rate of high-grade Clavien-Dindo events. The findings of this study suggest that there should be caution in extrapolating results about the safety profile of earlier generation lasers to the current 180-W LBO laser for patients on anticoagulation.
引用
- Knapp GL, Chalasani V, Woo HH, et al. Perioperative adverse events in patients on continued anticoagulation undergoing photoselective vaporisation of the prostate with the 180-W Greenlight lithium triborate laser. BJU Int. 2017. PMID: 28544292. doi:10.1111/bju.13822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。